Investigation of the Safety and Efficacy of JTT-751 in a Long-term Study in Hemodialysis Patients (1)
Phase 3
- Conditions
- Chronic Kidney Disease
- Registration Number
- JPRN-jRCT2080221397
- Lead Sponsor
- JAPAN TABACCO INC.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
Patients undergoing hemodialysis 3 times weekly
Exclusion Criteria
Patients with gastrointestinal diseases, such as peptic ulcer
Patients with advanced cardiac disease, or with hepatic dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum P levels
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does JTT-751 target in chronic kidney disease patients undergoing hemodialysis?
How does JTT-751 compare to standard-of-care treatments for hemodialysis patients with chronic kidney disease?
Are there specific biomarkers that predict response to JTT-751 in hemodialysis patients with chronic kidney disease?
What are the known or potential adverse events associated with JTT-751 in hemodialysis patients?
What related compounds or combination therapies are being explored for chronic kidney disease alongside JTT-751?